FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Forschung/FDA Proposes to Restrict Use of Semaglutide and Other Peptide Drugs in Compound Form
Zurück zur Forschungsbibliothek

FDA Proposes to Restrict Use of Semaglutide and Other Peptide Drugs in Compound Form

May 25, 2026
Share
Emergierende Forschung

Basiert auf emergierender Forschung. Diese Erkenntnisse sind versprechend, aber erfordern weitere Validierung.

Über diese Analyse

Diese Artikel sind eine AI-basierte Zusammenfassung eines kürzlich veröffentlichten Nachrichtenspieles oder einer klinischen Studienanzeige. Sie sind dazu gedacht, einen schnellen und zugänglichen Überblick für die Peptidforschungscommunity zu bieten. Für vollständige Genauigkeit empfehlen wir immer die unten angegebene Quelle zu überprüfen.

FDA Proposes to Restrict Use of Semaglutide and Other Peptide Drugs in Compound Form

The U.S. Food and Drug Administration (FDA) has proposed a significant change that could impact how certain peptide drugs are distributed and used within the healthcare system. The agency is considering excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances allowed under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA). This move could limit how these drugs are compounded in outsourcing facilities, affecting their availability for patients.

Background

Peptide drugs like semaglutide, tirzepatide, and liraglutide have become increasingly popular due to their effectiveness in treating conditions such as type 2 diabetes and obesity. These medications work by mimicking or enhancing the action of naturally occurring peptides in the body. The FDA’s decision to potentially exclude these drugs from the list of bulk substances that can be compounded is based on a lack of clinical evidence suggesting a need for them to be produced this way.

Outsourcing facilities play a crucial role in compounding medications, which involves mixing or assembling ingredients under sterile conditions to create personalized medications. The 503B bulks list includes approved active pharmaceutical ingredients (APIs) that these facilities can use to compound drugs. If the FDA’s proposal is finalized, outsourcing facilities would no longer be able to use bulk forms of semaglutide, tirzepatide, and liraglutide to create compounded medications.

Key Details

The proposed exclusion was announced in a recent press release from the FDA on April 30, 2026. The agency stated that there is no clinical need for these specific peptide drugs to be produced through compounding processes using bulk substances. This means that patients would likely have to rely solely on commercially manufactured versions of semaglutide, tirzepatide, and liraglutide.

The move by the FDA reflects a broader trend towards ensuring patient safety and quality control in pharmaceutical manufacturing. By restricting the use of these peptide drugs in compounded forms, the agency aims to prevent potential risks associated with improper compounding practices. However, this decision could also affect access to customized or tailored versions of these medications that some patients might need.

Key Takeaways

  • Clinical Need: The FDA determined there is no clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk substances.
  • Safety Considerations: This proposal aims to enhance patient safety by reducing the risk of improper compounding practices with these peptides.
  • Regulatory Changes: The decision could lead to changes in how these medications are distributed and used, impacting both healthcare providers and patients.
  • Patient Impact: Patients may need to rely more heavily on commercially manufactured versions of these drugs.

What This Means

For the peptide research community and clinicians working with these medications, this proposed change highlights the ongoing importance of FDA regulation in ensuring patient safety. While it could limit some compounding practices, it also underscores the agency’s commitment to maintaining high standards for pharmaceutical products. For patients currently using or considering these drugs, it means that personalized compounded versions might become less available.

The proposal is open for public comment and review, which provides an opportunity for stakeholders to voice their opinions on this significant regulatory change. As the FDA continues to evaluate feedback, the peptide community can expect further guidance and updates from the agency regarding these medications and potential implications for clinical practice.

---

Source: FDA Press Release — Published 2026-04-30

This article is for informational purposes only and does not constitute medical advice.

Bearbeitungsnotiz

Diese Analyse wurde mit AI-Tools generiert und durch den Peptide Contacts-Bearbeiterteam geprüft. Obwohl wir für die Genauigkeit streben, kann AI-generierter Inhalt Fehler oder Lücken enthalten. Wir ermutigen Leser, die ursprüngliche Quelle für vollständige Details, Methoden und Daten.

Peptide Contacts bietet vercurierte Forschungssummarien zur Informationszwecke an. Dieses Inhalte bilden keine medizinische Beratung aus. Stets beraten Sie sich mit einer qualifizierten Gesundheitsversorgerin, bevor Sie irgendeine Gesundheitsentscheidungen treffen.

Comments

Sign in to join the discussion

Dieser Artikel wurde mit AI generiert und kann ungenaue Informationen enthalten. Er wird zur Informationszwecke bereitgestellt und bildet keine medizinische Beratung aus. Stets überprüfen Sie die Information mit der ursprünglichen Quelle und beraten Sie sich mit einer qualifizierten Gesundheitsversorgerin, bevor Sie irgendeine Gesundheitsentscheidungen treffen.